BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1585 related articles for article (PubMed ID: 33975616)

  • 1. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
    Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osimertinib for
    Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
    Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
    Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
    Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
    Lee K; Kim D; Yoon S; Lee DH; Kim SW
    Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
    Joo JW; Hong MH; Shim HS
    Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in
    Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV
    Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.
    Auliac JB; Saboundji K; Andre M; Madelaine J; Quere G; Masson P; Vergnenegre A; Lamy R; Raymond S; Chiappa AM; Hauss PA; Fournel P; Corre R; Chouaid C
    Target Oncol; 2019 Jun; 14(3):307-314. PubMed ID: 31119481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
    Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
    Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
    Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
    Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
    Zhao Y; Li S; Yang X; Chu L; Wang S; Tong T; Chu X; Yu F; Zeng Y; Guo T; Zhou Y; Zou L; Li Y; Ni J; Zhu Z
    Int J Cancer; 2022 Apr; 150(8):1318-1328. PubMed ID: 34914096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
    Wang S; Yan B; Zhang Y; Xu J; Qiao R; Dong Y; Zhang B; Zhao Y; Zhang L; Qian J; Lu J; Zhao R; Han B
    Int J Cancer; 2019 Jun; 144(11):2880-2886. PubMed ID: 30474188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.